Research progress in immune checkpoint inhibitors for the treatment of cervical cancer / 国际生物医学工程杂志

Cervical cancer is a common gynecological malignancy. Currently, synchronous radiotherapy and chemotherapy based on the single drug cisplatin are the standard treatment regimen for locally advanced cervical cancer. Compared with simple radiotherapy and chemotherapy, the use of immunosuppressive combination regimens in concurrent radiotherapy and chemotherapy is more likely to improve local control and reduce distant metastasis. In recent years, immune checkpoint inhibitors (ICIs) have been widely studied as potential therapeutic targets for cervical cancer. Immunocheckpoint inhibitors can improve the activation of immune cells and enhance the body’s anti-tumor immunity. In this paper, the mechanism of immune checkpoint inhibitors was summarized, and the therapeutic effects of various monoclonal antibodies were reviewed to provide a new perspective for immunotherapy in patients with cervical cancer.

Research progress on the mechanism of CDK4/6 inhibitors promoting antitumor immunity by regulating the immune microenvironment of triple negative breast cancer / 国际肿瘤学杂志

Triple negative breast cancer is a subtype of breast cancer with poor prognosis and lack of effective treatment. Cyclin dependent kinase (CDK) 4/6 inhibitors promote antitumor immunity by influencing the triple negative breast cancer immune microenvironment, such as increasing the tumor cell surface pragrammed death-ligand 1 protein expression, enhancing T cell activation and antigen presentation, changing the proportion of T cell subgroup and inducing lymphocyte infiltration. The change of immune microenvironment is related to tumor progression, but its mechanism is extremely complex. Exploring the mechanism of CDK4/6 inhibitor affecting immune microenvironment and its biomarkers can provide a new direction for the diagnosis and treatment of triple negative breast cancer.

Research progress of biomarkers for predicting the efficacy of immunotherapy for tumor / 国际肿瘤学杂志

Immonocheckpoint inhabitors have become the focus of tumor therapy in recent years, and more and more tumor patients benefit from immunotherapy. Due to the high cost of immunotherapy, the benefit rate of immunotherapy for untested population is only 20%. Therefore, accurate selection of predictive biomarkers is crucial for individualized immunotherapy of tumor patients. Biomarkers reflecting tumor immune microenvironment and tumor cell intrinsic features, such as programmed death-1 (PD-1) and its ligand PD-L1, tumor mutational burden and microsatellite instability, have been proved to associate with treatment effect of anti-PD-1/anti-PD-L1 therapy. At the same time, markers based on tissue and serum emerge in endlessly. How to truly achieve accurate immunotherapy for tumor needs further clinical research.